Biotech stocks operate under a core ethos. While there’s been much talk about financially viable sectors – from tech to cryptocurrencies to even precious metals – when you think about it, nothing is more valuable than one’s health. If you can’t enjoy the fruits of your labor, then your labor will be meaningless. That’s why healthcare as a sector performs so well.Of course, being tied to a permanently relevant narrative doesn’t guarantee any individual enterprise success. However, one thing is clear. If you’ ...

SDI Productions/E+ via Getty Images Amgen Inc. (NASDAQ:AMGN) is one of the largest biopharmaceutical companies in the world, and it has been rapidly increasing its share of the global oncology medications market in recent years. Investment thesis The day after the company released its first-quarter 2024 financial results in early May, its share price rose more than 15%. In my opinion, the growth of Amgen's investment attractiveness in recent weeks is directly related to the successful integration of Horizon ...

Amgen (AMGN) announced that the FDA has granted approval to its leukemia drug, Blincyto, for consolidation treatment, regardless of measurable residual disease (MRD) status.Blincyto, a first-in-class Bispecific T-cell Engager (BiTE) therapy, is now approved for the treatment of adult and pediatric patients one month and older with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in the consolidation phase, regardless of MRD status. ALL is a fast-growing type of blood ca ...

BLINCYTO® Added to Multiphase Consolidation Chemotherapy Reduced Risk of Death by 58% Showing Superior Overall Survival Versus Chemotherapy AloneFirst and Only Bispecific T-cell Engager (BiTE®) Therapy for Consolidation Treatment Regardless of Measurable Residual Disease (MRD) StatusTHOUSAND OAKS, Calif., June 14, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) has approved BLINCYTO® (blinatumomab) for the treatment of adult and pediatric patients one mon ...

Ozempic and Wegovy (semaglutide for diabetes and weight loss, respectively) are popular weight-loss drugs that have taken the world by storm. Indeed, the craze is showing no signs of slowing down as more supply of GLP-1 receptor agonists comes online to meet blistering demand. Though demand is showing no signs of slowing, there’s already a great deal of competition going after a market that could grow to $100 billion by 2035, according to some analysts.Indeed, there’s some serious growth to be had for the c ...

Data Highlight Positive Outcomes in Uncontrolled Gout With KRYSTEXXA® and Progress in Addressing Sjögren's DiseaseTHOUSAND OAKS, Calif., June 12, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of data across its diverse portfolio and pipeline at the European Alliance of Associations for Rheumatology's (EULAR) 2024 Congress, June 12-15 in Vienna. The 27 abstracts from Amgen-sponsored and partner-led studies demonstrate Amgen's commitment to improving the lives of patients living wi ...

Amgen Inc. (NASDAQ:AMGN) Conference Call Summary Company Overview - **Company**: Amgen Inc. - **Event**: Goldman Sachs 45th Annual Global Healthcare Conference - **Date**: June 10, 2024 - **Participants**: - James E. Bradner – EVP of Research and Development & Chief Scientific Officer - Peter H. Griffith – EVP & CFO - Salveen Richter - Goldman Sachs Biotechnology Analyst Key Points Business Strategy and Focus Areas - Amgen is in a transformative period, expanding its global reach and advancing a diverse range of medicines, particularly in obesity, oncology, inflammation, and rare diseases [4][6] - The company is committed to creating value for patients, staff, and shareholders [4] Obesity Treatment: MariTide - MariTide is a major focus, with confidence in its differentiated profile and potential impact on obesity-related conditions [5][14] - A broad Phase 3 program is being planned, with manufacturing capabilities being expanded [5] - The Phase 2 study has shown promising interim results, with a full data set expected by the end of the year [14][50] Therapeutic Areas and Product Pipeline - Amgen has strong momentum across four therapeutic pillars: general medicine, oncology, inflammation, and rare diseases, each with significant growth potential [6] - Recent approvals include IMDELLTRA for small cell lung cancer and positive Phase 3 data for UPLIZNA in IgG4-related disease, showing an 87% reduction in disease flare risk [7][8] - The rare disease portfolio, including products like TEPEZZA and KRYSTEXXA, generated nearly $1 billion in sales in the first quarter [10] Financial Performance and Growth - Total non-GAAP operating expenses are expected to grow at a rate comparable to the first quarter, which saw a 33% year-over-year increase [11] - CAPEX expenditures are projected at $1.1 billion to $1.2 billion for the year [11] Manufacturing and Supply Chain - Amgen is enhancing its manufacturing capabilities with new state-of-the-art facilities in North Carolina and Ohio, focusing on automation and efficiency [19][20] - The company has maintained a strong supply chain, which was crucial during the COVID-19 pandemic [20] Capital Allocation and Financial Strategy - Amgen's capital allocation strategy prioritizes investment in innovation and business growth, with a focus on returning capital to shareholders [52] - The company plans to return to pre-Horizon leverage levels by the end of 2025 and has increased its dividend by 6% to $2.25 per share [52][53] Competitive Landscape and Market Positioning - Amgen is positioning its products, such as MariTide and TEZSPIRE, to address significant unmet medical needs in obesity and chronic obstructive pulmonary disease (COPD) [27][30] - The company is also exploring the potential of its bispecific T-cell engagers in autoimmune diseases, leveraging its expertise in the CD19 pathway [35][38] Future Outlook - Amgen is optimistic about the upcoming Phase 3 data for several products, including Olpasiran and rocatinlumab, which are expected to provide insights into their efficacy and market positioning [26][32] - The company is focused on expanding its global footprint and enhancing access to its medicines, particularly in rare diseases [46][48] Additional Insights - The integration of Horizon's assets has been seamless, enhancing Amgen's R&D capabilities and market presence [46] - The company is committed to addressing the needs of patients with serious illnesses through its innovative pipeline and strategic partnerships [12][50] This summary encapsulates the key points discussed during the conference call, highlighting Amgen's strategic focus, product pipeline, financial performance, and future outlook.

Core Viewpoint - Amgen's stock has underperformed compared to the broader market and the Medical sector, with upcoming earnings expected to show a decline in EPS but an increase in revenue [1][2]. Group 1: Stock Performance - Amgen closed at $305.02, reflecting a -0.22% change from the previous day, which is slightly better than the S&P 500's loss of 0.11% [1]. - Over the last month, Amgen's shares decreased by 2.29%, while the Medical sector gained 4.12% and the S&P 500 gained 3.51% [1]. Group 2: Earnings Estimates - The upcoming EPS for Amgen is projected at $4.86, indicating a 2.8% decline compared to the same quarter last year [1]. - Revenue for the upcoming quarter is estimated at $8.27 billion, representing an 18.34% increase from the prior-year quarter [1]. - For the entire fiscal year, earnings are projected at $19.47 per share and revenue at $32.98 billion, reflecting changes of +4.4% and +17.01% respectively from the prior year [1]. Group 3: Analyst Estimates and Valuation - Recent analyst estimate revisions for Amgen have shown a 0.06% increase in the Zacks Consensus EPS estimate over the past month [2]. - Amgen currently holds a Zacks Rank of 3 (Hold), indicating a neutral outlook based on analyst estimates [2]. - The Forward P/E ratio for Amgen is 15.7, which is lower than the industry average of 22.87, suggesting that Amgen is trading at a discount [3]. - Amgen's PEG ratio stands at 2.76, compared to the industry average of 2.12, indicating a higher expected earnings growth rate relative to its price [3]. - The Medical - Biomedical and Genetics industry, which includes Amgen, has a Zacks Industry Rank of 83, placing it in the top 33% of over 250 industries [3].

Amgen (AMGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Over the past month, shares of this world's largest biotech drugmaker have returned -2.3%, compared to the Zacks S&P 500 composite's +3.5% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which Amgen falls in, has gained 2.2%. The key question now is: What could be the stock's future direction ...

Amgen (AMGN) announced positive results from the phase III MITIGATE study, which evaluated its rare disease drug Uplizna (inebilizumab) for treating Immunoglobulin G4-related disease (IgG4-RD), a rare inflammatory condition.The MITIGATE study achieved its primary endpoint — patients treated with Uplizna over a 52-week period showed a statistically significant 87% reduction in the risk of IgG4-RD flare when compared with a placebo. The study also achieved key secondary endpoints, which include annualized fla ...